Vera Therapeutics Inc (VERA) - News Archive

Vera Therapeutics Makes Significant Strides in IgA Nephropathy Treatment with Positive Phase 3 Data for Atacicept and Strategic Inducement Grants BRISBANE, Calif., Nov. 6, 2025 Vera Therapeutics, Inc. (Nasdaq: VERA), a...

In a strategic move to bolster its workforce and drive forward its mission of developing transformative therapies for patients with immunological diseases, Vera Therapeutics, Inc. (Nasdaq: VERA), a forward-thinking biop...

Vera Therapeutics, Inc. (Nasdaq: VERA), a prominent player in pharmaceutical innovation, has made strides in expanding its team by offering generous inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4...

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): A Commitment to Team Growth and Sustaining Momentum in 2025BRISBANE, Calif. In an ongoing commitment to expand its talent pool and enhanc...

BRISBANE, Calif. Jan. 13, 2025 — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology firm dedicated to developing transformative treatments for serious immunological diseases, has made a signific...

Brisbane, Calif. December 9, 2024 In a notable move to attract top talent and bolster its leadership trajectory, Vera Therapeutics, Inc. (Nasdaq: VERA) has announced a series of inducement awards aimed at newly hired em...

Vera Therapeutics, Inc. (Nasdaq: VERA), a leading biotechnology company focused on developing transformative therapies for autoimmune diseases, has made significant strides in bolstering its executive expertise with the...

A Strategic Drive: Vera Therapeutics Inducement Awards and Public Offering Propel Shareholder ConfidenceIn recent developments that underscore Vera Therapeutics, Inc. s strategic efforts to bolster its talent pool and f...

Vera Therapeutics Partners with University of Michigan Amid Revenue Challenges BRISBANE, Calif. Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology firm focused on development and commercializati...

Vera Therapeutics Explores New Horizons with $300 Million Public Offering: A Strategic Move Amidst Impressive Year-to-Date GainsIn a bold move signaling its commitment to growth and innovation, Vera Therapeutics, Inc. h...

Navigating Clinical Progress and Market Challenges: Vera Therapeutics’ ORIGIN Phase 2b Trial Results at ASN Kidney Week 2024 Vera Therapeutics recently announced a late-breaking oral presentation of the long-term result...

Vera Therapeutics, Inc. a late clinical-stage biotechnology company dedicated to developing transformative treatments for severe immunological disorders, has announced the completion of patient enrollment for the primar...

BRISBANE, Calif., Aug. 09, 2024 - Vera Therapeutics, Inc. (Nasdaq: VERA), a pioneering biopharmaceutical company, made a significant announcement today that has far-reaching implications for its shareholders and the com...

Vera Therapeutics Grants Inducement Awards to New Employees in Accordance with Nasdaq Listing Rule 5635(c)(4)Vera Therapeutics, a biopharmaceutical company based in Brisbane, California, recently announced the granting...

In a recent press release, Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing groundbreaking treatments for patients with serious immunologic diseases, announced th...

In an exciting development for the biotechnology industry, Vera Therapeutics, Inc. (Vera) has announced the successful closure of its underwritten public offering. Late-stage clinical biotech company Vera focuses on dev...

Vera Therapeutics, Inc. Sets Sights on Advancing Immunologic Disease Treatments with Upsized Public OfferingBRISBANE, Calif., Jan. 29, 2024 - Vera Therapeutics, Inc. (Vera), a leading biotechnology company focused on de...

IgA nephropathy is a chronic kidney disease characterized by the deposition of IgA immunoglobulins in the glomeruli. It is the most common primary glomerulonephritis worldwide, often resulting in progressive decline in...

Vera Therapeutics Strengthens Leadership Team with Industry Veterans to Drive Drug Program DevelopmentBrisbane, Calif. - In a significant move to further advance its drug programs, late clinical-stage biotechnology comp...